Combined Therapy of Interferon Plus Ribavirin Promotes Multiple Adaptive Solutions in Hepatitis C Virus
Por:
Cuevas, J, Torres-Puente, M, Jimenez-Hernandez, N, Bracho, M, Garcia-Robles, I, Carnicer F, del Olmo, J, Ortega, E, Gonzalez-Candelas, F and Moya, A
Publicada:
1 abr 2009
Resumen:
Hepatitis C virus (HCV) presents several regions involved potentially in evading antiviral treatment and host immune system. Two regions, known as PKR-BD and V3 domains, have been proposed to be involved in resistance to interferon. Additionally, hypervariable regions in the envelope E2 glycoprotein are also good candidates to participate in evasion from the immune system. In this study, we have used a cohort of 22 non-responder patients to combined therapy (interferon alpha-2a plus ribavirin) for which samples obtained just before initiation of therapy and after 6 or/and 12 months of treatment were available. A range of 25-100 clones per patient, genome region and time sample were obtained. The predominant amino acid sequences for each time sample and patient were determined. Next, the sequences of the PKR-BD and V3 domains and the hypervariable regions from different time samples were compared for each patient. The highest levels of variability were detected at the three hypervariable regions of the E2 protein and,to a lower extent, at the V3 domain of the NS5A protein. However, no clear patterns of adaptation to the host immune system or to antiviral treatment were detected. In summary, although high levels of variability are correlated to viral adaptive response, antiviral treatment does not seem to promote convergent adaptive changes. Consequently, other regions must be involved in evasion strategies likely based on a combination of multiple mechanisms, in which pools of changes along the HCV genome could confer viruses the ability to overcome strong selective pressures. J. Med. Virol. 81:650656, 2009. (C) 2009 Wiley-Liss, Inc.
Filiaciones:
Cuevas, J:
Univ Valencia, Inst Cavanilles Biodiversidad & Biol Evolut, Dept Genet, Valencia 46071, Spain
CIBERESP, Barcelona, Spain
:
Univ Valencia, Inst Cavanilles Biodiversidad & Biol Evolut, Dept Genet, Valencia 46071, Spain
:
Univ Valencia, Inst Cavanilles Biodiversidad & Biol Evolut, Dept Genet, Valencia 46071, Spain
CIBERESP, Barcelona, Spain
CSISP, Area Genom & Salud, Valencia, Spain
:
Univ Valencia, Inst Cavanilles Biodiversidad & Biol Evolut, Dept Genet, Valencia 46071, Spain
CIBERESP, Barcelona, Spain
CSISP, Area Genom & Salud, Valencia, Spain
Garcia-Robles, I:
Univ Valencia, Inst Cavanilles Biodiversidad & Biol Evolut, Dept Genet, Valencia 46071, Spain
Carnicer F:
Hosp Gen Alicante, Unidad Hepatol, Alicante, Spain
del Olmo, J:
Hosp Clin Valencia, Serv Hepatol, Valencia, Spain
Ortega, E:
Hosp Gen Valencia, Unidad Enfermedades Infecciosas, Valencia, Spain
:
Univ Valencia, Inst Cavanilles Biodiversidad & Biol Evolut, Dept Genet, Valencia 46071, Spain
CIBERESP, Barcelona, Spain
CSISP, Area Genom & Salud, Valencia, Spain
:
Univ Valencia, Inst Cavanilles Biodiversidad & Biol Evolut, Dept Genet, Valencia 46071, Spain
CIBERESP, Barcelona, Spain
CSISP, Area Genom & Salud, Valencia, Spain
|